Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in…